TY  - JOUR
T1  - Evaluation of the Role of Antiplatelet Medications in Cardiovascular Disease
A1  - Abdulrahman Saad S Althobaiti
A1  - Abdullah Wajih A Alammari
A1  - Ali Ahmed A Alalawi
A1  - Nawaf Oudah S Alhawiti
A1  - Asem Yousif Al-Balawi
A1  - Muhand Ali A Asseri
A1  - Ahmed Saleh Al Saed
A1  - Manal Mohamed Saud
A1  - Salem Ahmed S Shaman
A1  - Omar Kamel Alqatrawi
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2021
VL  - 12
IS  - 2
DO  - 10.51847/UJvNwTZfsZ
SP  - 97
EP  - 103
N2  - Cardiovascular disease (CVD) and its complications are the most common causes of mortality and morbidity worldwide. It is shown that patients with myocardial infarctions (MIs) have high platelets activation and aggregation rates which lead to atherothrombosis after the rupture of an unstable atherosclerotic plaque. Therefore, antiplatelet therapy has become an important part of the secondary prevention of cardiovascular disease. To provide a review about the role of antiplatelet medications in preventing cardiovascular disease and its complications. The articles were selected in regards to the inclusion criteria, based on the incorporation of one of the following topics: antiplatelet action in cardiovascular disease. Exclusion principles were all other articles, which did not have one of these topics as their essential endpoint. PubMed database was utilized for articles selection, and the following keys were used in the mesh ((“antiplatelet"[Mesh]) AND (“cardiovascular disease” [Mesh]) OR (“DAPT"[Mesh])).

Aspirin was the first antiplatelet medicine identified, and it is still recommended as the first line of defense in the secondary prevention of cardiovascular disease. For many years, clopidogrel has been the predominant P2Y12 inhibitor in the acute context. peripheral angioplasty with stenting or Following elective percutaneous coronary intercession (PCI), the state-of-the-art dual antiplatelet treatment (DAPT) regimen includes clopidogrel plus aspirin. The appropriate DAPT length following stent implantation has been a topic of extreme controversy and considerable scientific interest. More research is necessary to determine the optimal duration that is safe and effective for post-PCI patients
UR  - https://pharmacophorejournal.com/article/evaluation-of-the-role-of-antiplatelet-medications-in-cardiovascular-disease-1yx8u6njyxw33wm
ER  -